Anti-tumor activity of valproic acid in EBV-positive Burkitt lymphoma via PFN2-associated PI3K/AKT pathway repression
Yongliang Zheng, Yuxiu Yang, Shouhua Zhang, Rui Liu, Zujie Lin, Yuanqiao He, Yaoling Luo, Aili He · 2026
Read Anti-tumor activity of valproic acid in EBV-positive Burkitt lymphoma via PFN2-associated PI3K/AKT pathway repression by Yongliang Zheng, Yuxiu Yang, Shouhua Zhang, Rui Liu, Zujie Lin, Yuanqiao He, Yaoling Luo, Aili He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617333.txt.
Description
Yongliang Zheng and co-authors test an old drug, valproic acid, against a fast-growing blood cancer in a 2026 study. The cancer is Burkitt lymphoma tied to the Epstein-Barr virus, and options are few for older or relapsed patients. The team tried the drug on three cell lines in the lab and on tumors grown in mice, some taken from real patients.
The drug slowed cell growth, pushed cells toward death, and shrank tumors in the mice. Gene tests pointed to a protein called PFN2 and a growth pathway that the drug turns down. Blocking that pathway on its own, or with the drug, added to the effect in follow-up tests. The work names a clear path for further study of this drug in this cancer.
Catalog record
| CREATOR | Yongliang Zheng, Yuxiu Yang, Shouhua Zhang, Rui Liu, Zujie Lin, Yuanqiao He, Yaoling Luo, Aili He |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |